Patents by Inventor Marialuisa Lavitrano
Marialuisa Lavitrano has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9820987Abstract: The described invention provides a method of treating a patient with an epithelial cancer comprising administering a composition comprising a therapeutic amount of an inhibitor of a BTK protein and one or more chemotherapeutic agent(s) selected from the group consisting of an antimetabolite, a platinum coordination compound, an alkylating agent and a combination thereof, wherein the composition is effective to reduce one or more of tumor cell growth, tumor cell clonogenicity, tumor cell proliferation, tumor cell viability and tumor volume and the therapeutic amount of the inhibitor of a BTK protein and the one or more chemotherapeutic agent(s) exerts a synergistic effect. The described invention also provides methods of treating a chemotherapy drug-resistant cancer and sensitizing a cancer patient to chemotherapy.Type: GrantFiled: December 30, 2014Date of Patent: November 21, 2017Assignee: Bionsil S.R.L. in LiquidazioneInventors: Marialuisa Lavitrano, Emanuela Grassilli, Kristian Helin
-
Publication number: 20160193211Abstract: The present application describes therapies for the effective treatment of colon and colorectal carcinomas. The present invention relates to a pharmaceutical kit, comprising combinations of a BTK inhibitor and fluorouracil, for the treatment of colon and colorectal carcinomas also in the case in which such carcinomas are drug resistant and therefore allows to overcome cancer drug resistance.Type: ApplicationFiled: August 4, 2014Publication date: July 7, 2016Inventors: Marialuisa LAVITRANO, Emanuela GRASSILLI, Roberto GIOVANNONI, Fabio PISANO, Gabriele ROMANO, Laura MASIERO, Maria Grazia CERRITO
-
Patent number: 9068200Abstract: The present invention refers to a method for the transfer of DNA sequences or exogenous genes into animal sperm cells by means of the use of episomal vectors. The invention also relates to the use of “Sperm Mediated Gene Transfer” (SMGT) technology for the creation of genetically modified individuals.Type: GrantFiled: October 5, 2005Date of Patent: June 30, 2015Assignee: UNIVERSITA' DEGLI STUDI MILANO-BICOCCAInventors: Marialuisa Lavitrano, Maria Laura Bacci, Monica Forni, Hans Joachim Lipps, Pierluigi Donini
-
Publication number: 20150150899Abstract: The use of compounds is described which are capable of functionally blocking at least one of the genes chosen from the group composed of EphAI, EphA2, EphA8, EphB2, CSF1R, VEGFR2, RAMP2, RAMP3, CLRN1, MAPK4, PIK3C2A, PIK3CG, GSK3alpha, GSK3beta, IRAK3, DAPK1, JAK1, PIM1, TRB3, BTG1, LATS1, LIMK2, MYLK, PAK1, PAK2, CDC2, BTK, PNRC2, NCOA4, NR2C1, TPR, RBBP8, TRPC7, FXYD1, ERNI, PRSS16, RPS3, CCL23 and SERPINE1, for the manufacture of a medicament destined to diminish the resistance to chemotherapeutic drugs in the therapeutic treatment of epithelial tumor pathologies. Also described is a method for the determination of the drug resistance in tumor cells, as well as a method for the identification of tumor stem cells.Type: ApplicationFiled: October 14, 2014Publication date: June 4, 2015Applicant: BIONSIL S.R.L.Inventors: Marialuisa Lavitrano, Emanuela Grassilli, Kristian Helin
-
Publication number: 20150111953Abstract: The described invention provides a method of treating a patient with an epithelial cancer comprising administering a composition comprising a therapeutic amount of an inhibitor of a BTK protein and one or more chemotherapeutic agent(s) selected from the group consisting of an antimetabolite, a platinum coordination compound, an alkylating agent and a combination thereof, wherein the composition is effective to reduce one or more of tumor cell growth, tumor cell clonogenicity, tumor cell proliferation, tumor cell viability and tumor volume and the therapeutic amount of the inhibitor of a BTK protein and the one or more chemotherapeutic agent(s) exerts a synergistic effect. The described invention also provides methods of treating a chemotherapy drug-resistant cancer and sensitizing a cancer patient to chemotherapy.Type: ApplicationFiled: December 30, 2014Publication date: April 23, 2015Inventors: Marialuisa Lavitrano, Emanuela Grassilli, Kristian Helin
-
Patent number: 8889643Abstract: The use of compounds is described which are capable of functionally blocking at least one of the genes chosen from the group composed of EphAI, EphA2, EphA8, EphB2, CSF1R, VEGFR2, RAMP2, RAMP3, CLRN1, MAPK4, PIK3C2A, PIK3CG, GSK3alpha, GSK3beta, IRAK3, DAPK1, JAK1, PIM1, TRB3, BTG1, LATS1, LIMK2, MYLK, PAK1, PAK2, CDC2, BTK, PNRC2, NCOA4, NR2C1, TPR, RBBP8, TRPC7, FXYD1, ERNI, PRSS16, RPS3, CCL23 and SERPINE1, for the manufacture of a medicament destined to diminish the resistance to chemotherapeutic drugs in the therapeutic treatment of epithelial tumor pathologies. Also described is a method for the determination of the drug resistance in tumor cells, as well as a method for the identification of tumor stem cells.Type: GrantFiled: June 25, 2012Date of Patent: November 18, 2014Assignee: Bionsil, S.r.l.Inventors: Marialuisa Lavitrano, Emanuela Grassilli, Kristian Helin
-
Publication number: 20130041014Abstract: The use of compounds is described which are capable of functionally blocking at least one of the genes chosen from the group composed of EphAl, EphA2, EphA8, EphB2, CSF1R, VEGFR2, RAMP2, RAMP3, CLRN1, MAPK4, PIK3C2A, PIK3CG, GSK3alpha, GSK3beta, IRAK3, DAPK1, JAK1, PIM1, TRB3, BTG1, LATS1, LIMK2, MYLK, PAK1, PAK2, CDC2, BTK, PNRC2, NCOA4, NR2C1, TPR, RBBP8, TRPC7, FXYD1, ERNI, PRSS16, RPS3, CCL23 and SERPINE1, for the manufacture of a medicament destined to diminish the resistance to chemotherapeutic drugs in the therapeutic treatment of epithelial tumour pathologies. Also described is a method for the determination of the drug resistance in tumour cells, as well as a method for the identification of tumour stem cells.Type: ApplicationFiled: June 25, 2012Publication date: February 14, 2013Applicant: BIONSIL S.R.L.Inventors: Marialuisa Lavitrano, Emanuela Grassilli, Kristian Helin
-
Publication number: 20130041012Abstract: The use of compounds is described which are capable of functionally blocking at least one of the genes chosen from the group composed of EphAI, EphA2, EphA8, EphB2, CSF1R, VEGFR2, RAMP2, RAMP3, CLRN1, MAPK4, PIK3C2A, PIK3CG, GSK3alpha, GSK3beta, IRAK3, DAPK1, JAK1, PIM1, TRB3, BTG1, LATS1, LIMK2, MYLK, PAK1, PAK2, CDC2, BTK, PNRC2, NCOA4, NR2C1, TPR, RBBP8, TRPC7, FXYD1, ERNI, PRSS16, RPS3, CCL23 and SERPINE1, for the manufacture of a medicament destined to diminish the resistance to chemotherapeutic drugs in the therapeutic treatment of epithelial tumour pathologies. Also described is a method for the determination of the drug resistance in tumour cells, as well as a method for the identification of tumour stem cells.Type: ApplicationFiled: June 25, 2012Publication date: February 14, 2013Applicant: BIONSIL S.R.L.Inventors: Marialuisa Lavitrano, Emanuela Grassilli, Kristian Helin
-
Publication number: 20130041013Abstract: The use of compounds is described which are capable of functionally blocking at least one of the genes chosen from the group composed of EphA1, EphA2, EphA8, EphB2, CSF1R, VEGFR2, RAMP2, RAMP3, CLRN1, MAPK4, PIK3C2A, PIK3CG, GSK3alpha, GSK3beta, IRAK3, DAPK1, JAK1, PIM1, TRB3, BTG1, LATS1, LIMK2, MYLK, PAK1, PAK2, CDC2, BTK, PNRC2, NCOA4, NR2C1, TPR, RBBP8, TRPC7, FXYD1, ERNI, PRSS16, RPS3, CCL23 and SERPINE1, for the manufacture of a medicament destined to diminish the resistance to chemotherapeutic drugs in the therapeutic treatment of epithelial tumour pathologies. Also described is a method for the determination of the drug resistance in tumour cells, as well as a method for the identification of tumour stem cells.Type: ApplicationFiled: June 25, 2012Publication date: February 14, 2013Applicant: BIONSIL S.R.L.Inventors: Marialuisa Lavitrano, Emanuela Grassilli, Kristian Helin
-
Patent number: 8232085Abstract: The use of compounds is described which are capable of functionally blocking at least one of the genes chosen from the group composed of EphA1, EphA2, EphA8, EphB2, CSF1R, VEGFR2, RAMP2, RAMP3, CLRN1, MAPK4, PIK3C2A, PIK3CG, GSK3alpha, GSK3beta, IRAK3, DAPK1, JAK1, PIM1, TRB3, BTG1, LATS1, LIMK2, MYLK, PAK1, PAK2, CDC2, BTK, PNRC2, NCOA4, NR2C1, TPR, RBBP8, TRPC7, FXYD1, ERN1, PRSS16, RPS3, CCL23 and SERPINE1, for the manufacture of a medicament destined to diminish the resistance to chemotherapeutic drugs in the therapeutic treatment of epithelial tumor pathologies. Also described is a method for the determination of the drug resistance in tumor cells, as well as a method for the identification of tumor stem cells.Type: GrantFiled: March 14, 2008Date of Patent: July 31, 2012Assignee: Bionsil S.R.L.Inventors: Marialuisa Lavitrano, Emanuela Grassilli, Kristian Helin
-
Publication number: 20100081704Abstract: The use of compounds is described which are capable of functionally blocking at least one of the genes chosen from the group composed of EphA1, EphA2, EphA8, EphB2, CSF1R, VEGFR2, RAMP2, RAMP3, CLRN1, MAPK4, PIK3C2A, PIK3CG, GSK3alpha, GSK3beta, IRAK3, DAPK1, JAK1, PIM1, TRB3, BTG1, LATS1, LIMK2, MYLK, PAK1, PAK2, CDC2, BTK, PNRC2, NCOA4, NR2C1, TPR, RBBP8, TRPC7, FXYD1, ERN1, PRSS16, RPS3, CCL23 and SERPINE1, for the manufacture of a medicament destined to diminish the resistance to chemotherapeutic drugs in the therapeutic treatment of epithelial tumour pathologies. Also described is a method for the determination of the drug resistance in tumour cells, as well as a method for the identification of tumour stem cells.Type: ApplicationFiled: March 14, 2008Publication date: April 1, 2010Applicant: UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCAInventors: Marialuisa Lavitrano, Emanuela Grassilli, Kristian Helin
-
Publication number: 20090158450Abstract: The present invention refers to a method for the transfer of DNA sequences or exogenous genes into animal sperm cells by means of the use of episomal vectors. The invention also relates to the use of “Sperm Mediated Gene Transfer” (SMGT) technology for the creation of genetically modified individuals.Type: ApplicationFiled: October 5, 2005Publication date: June 18, 2009Inventors: Marialuisa Lavitrano, Maria Laura Bacci, Monica Forni, Hans Joachim Lipps, Pierluigi Donini
-
Publication number: 20050053910Abstract: The invention relates to cell culture media more particularly to fertilisation media, to making and using transgenes, to providing sperm cells for fertilisation particularly in applications such as sperm-mediated gene transfer and to using sperm cells for generating transgenic animals.Type: ApplicationFiled: October 2, 2002Publication date: March 10, 2005Inventors: Ian McKenzie, Mauro Sandrin, Nicole Webster, Marialuisa Lavitrano